| Dr. Rainer Lichtenberger, CEO, has more than 20 years of management experience in renowned companies. Being Pharmacist by training he joined Merck KGaA in 1988 after finishing his Ph.D. thesis in Pharmaceutical Technology. With Merck KGaA, he held various positions of increasing responsibility in R&D, project management and global marketing, among them head business unit „Osteoporosis & Womens Health and vice president of global marketing. In 2002 Dr. Lichtenberger joined the Merckle/ratiopharm group on executive board level, in his role as corporate vice president business development and international marketing. Since 2004 he established a private venture-financed German biopharmaceutical development company, Neuraxo Biopharmaceuticals GmbH, out of an university spin-off and managed a major series A venture round with 12 Mio. € volume in 2005.
|
| Wolfgang Kintzel, Chief Marketing & Sales Officer, earned a master of science in molecular biology from University Bochum, Germany. After that he gained more than 15 years of experience in different roles of increasing responsibility within the pharmaceutical, medical device and biotech industry in leading European and US based organizations. From 2000 - 2008 he built up amaxa AG, since 2008 Lonza AG, as global VP Marketing & Sales from a start-up situation to a fully integrated company and had full P&L responsibility for 25+ Mio. € Sales complemented with an outstanding M&A experience in 2008.
|
| Dr. Gudrun Schiedner, CSO, has studied Biology in Konstanz and received a PhD in Molecular Genetics and Virology from the University of Cologne. After several years as Senior Scientist at the Baylor College of Medicine/Huston USA, in 1996 she joined the Gene Therapy Division of the Center for Molecular Medicine in Cologne. Since 2003 she has been Head of Cell Line and Vector Development, since 2005 CSO of CEVEC.
|
